"Celebration" for Promise of New Melanoma Drugs at ASCO

June 6, 2011

The New York Times

Two melanoma drug breakthroughs were reported at the American Society of Clinical Oncology meeting in Chicago on Sunday, providing new hope for patients diagnosed with the deadly skin cancer, who have had no new treatment options for more than two decades. Lynn Schuchter, MD, chief of the division of Hematology-Oncology and director of the melanoma program in the Abramson Cancer Center, is quoted widely in the press about the two new approaches to treating the disease – one, a drug that attacks the tumor-growth accelerating BRAF mutation, carried by about half of all melanoma patients, and the other an immunotherapeutic agent called Yervoy which was recently approved by the FDA. "This is an unprecedented time of celebration for our patients," Schuchter told the New York Times, in a story that ran on the front page of today's paper. She was also quoted by Reuters and in an Associated Press story, along with one of her patients, which ran in several dozen newspapers nationwide and multiple online news outlets. "This is going to be a revolutionary way to treat patients with cancer," Schuchter said on ABC World News Tonight, which also featured an Abramson Cancer Center patient. "We have tears of joy in clinic when we have a patient who's really sick from melanoma, and we've enrolled them on these clinical trials, and in 72 hours, they're better. This is unbelievable." Read More

Visit msnbc.com for breaking news, world news, and news about the economy

Additional Coverage